Mizuho Maintains Buy on ADMA Biologics, Raises Price Target to $9

Benzinga · 01/22 14:15
Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price target from $7 to $9.